Research programme: anticancer monoclonal antibodies - MabVax/MSKCCAlternative Names: 1B7; 1B7/31F; r5B1
Latest Information Update: 29 Apr 2016
At a glance
- Originator MabVax Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action GD2 ganglioside modulators; Tumour-associated carbohydrate antigen modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer